Move to topTop
Terumo Aortic today announced the first North American implant of a novel custom-made hybrid device, Thoracoflo™, which is used to treat patients with thoracoabdominal aortic disease using a less invasive surgical technique than traditional open surgical repair.

This thoracoabdominal repair procedure using Thoracoflo™ was carried out by Dr Randy Moore, Co-Director of the Calgary Complex Aortic Program at the University of Calgary in Canada. Dr Moore and the team at University of Calgary were supported by Professor Sabine Wipper, Chair of Vascular Surgery, University Hospital Innsbruck, Austria, who continues to be a key contributor to the development of the device. Dr Moore was able to access the device through the Health Canada Special Access program and this represents a further important stage in the development of this unique device to treat a broader range of patients who are not suitable for treatment with an off-the-shelf product. The lead center in Europe for this unique hybrid procedure is the University Heart Center in Hamburg, under the direction of Professor Sebastian Debus.

Dr Randy Moore commented: “This unique hybrid graft was designed through Terumo Aortic’s custom device program, specifically for the patient we were treating. With no other device with similar technology currently available globally for thoracoabdominal aortic repair, the Thoracoflo™ graft is designed to reduce the risk of complications associated with thoracotomy and extracorporeal circulation. This is the first time the device has been implanted in North America; it was easy to implant, and the procedure was uneventful and straightforward. The patient is recovering well with no complications post-operatively.” 

John Canning, Chief Technology and Marketing Officer at Terumo Aortic said: “This expansion into North America represents a significant commitment to developing patient specific solutions to treat a wider group of patients as part of our comprehensive surgical, endovascular and hybrid portfolio.”

Thoracoflo™ incorporates a combination of Terumo Aortic’s proven Gelweave™ woven polyester grafts and unique ring-stent technology to address the patient’s specific anatomy.


About Terumo Aortic   

At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility, and precision with the broadest range of solutions that can be personalised for every patient. We are further complementing our implantable device portfolio through the development of digital technologies.


Notes to Editors

  • Terumo acquired Vascutek Ltd. in 2002 and Bolton Medical Inc. in 2017 
  • Terumo Aortic has over 1,250 employees around the world with manufacturing facilities in Glasgow, Scotland and Sunrise, Florida. 


About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.